FY2024 EPS Estimates for ATOS Lifted by Cantor Fitzgerald

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Equities researchers at Cantor Fitzgerald raised their FY2024 EPS estimates for Atossa Therapeutics in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of ($0.20) per share for the year, up from their prior estimate of ($0.22). The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.21) per share.

A number of other equities analysts also recently issued reports on ATOS. HC Wainwright raised their price objective on Atossa Therapeutics from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Ascendiant Capital Markets boosted their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, StockNews.com lowered shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday.

Atossa Therapeutics Stock Performance

Shares of ATOS opened at $1.28 on Monday. The stock’s 50-day moving average price is $1.44 and its two-hundred day moving average price is $1.37. Atossa Therapeutics has a 12 month low of $0.67 and a 12 month high of $2.31. The company has a market capitalization of $161.02 million, a PE ratio of -5.93 and a beta of 1.23.

Institutional Investors Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC increased its holdings in Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company’s stock worth $255,000 after purchasing an additional 123,683 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock worth $4,278,000 after buying an additional 44,762 shares during the period. XTX Topco Ltd increased its stake in shares of Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company’s stock valued at $75,000 after acquiring an additional 24,951 shares in the last quarter. State Street Corp lifted its position in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after acquiring an additional 69,180 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new position in Atossa Therapeutics during the third quarter worth $75,000. Institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.